Seelos Therapeutics, Inc.
https://seelostherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Seelos Therapeutics, Inc.
Relyvrio’s Failure Sparks NeuroSense ALS Development Changes
NeuroSense plans to adjust its upcoming clinical trial to avoid the fate of Amylyx’s ALS candidate, which was recently withdrawn from the market due to a lack of efficacy.
Seelos Aims For Conservative Approach After ALS Drug Shows Efficacy Signal
CEO Raj Mehta told Scrip Seelos anticipates conducting a Phase III study of SLS-005 after the cohort in HEALEY ALS failed overall, but indicated some efficacy in patients not receiving Relyvrio.
Seelos Forges Ahead With SLS-002, Says Primary Endpoint Miss Due To Underpowered Trial
The company blamed lack of funding for incomplete enrollment of the Phase II study in acute suicidal ideation and behavior in major depressive disorder, saying it would have reached statistical significance had it fully enrolled.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Apricus Biosciences, Inc.
- Apricus Pharma
- NexMed USA
- TopoTarget USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice